Skip to main content

Advertisement

SpringerLink
Log in

Accelerating innovations in systemic therapy for pleural mesothelioma

  • Clinical Outlook
  • Published:

From Nature Cancer

View current issue Submit your manuscript

Malignant pleural mesothelioma is a challenging disease with few approved treatments. Rapidly expanding insights into the pathogenesis of this cancer and clinical trials are now suggesting a variety of targeted and immune-oncology agents with the potential to address unmet clinical needs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Timeline of key developments in systemic therapy for patients with MPM.

References

  1. Nicholson, A. G. et al. J. Thorac. Oncol. 15, 29–49 (2020).

    Article  CAS  Google Scholar 

  2. Baas, P. et al. Lancet 397, 375–386 (2021).

    Article  CAS  Google Scholar 

  3. Szlosarek, P. W. et al. JAMA Oncol. 3, 58–66 (2017).

    Article  Google Scholar 

  4. Hmeljak, J. et al. Cancer Discov. 8, 1548–1565 (2018).

    Article  CAS  Google Scholar 

  5. Zauderer, M. G. et al. Lancet Oncol. 23, 758–767 (2022).

    Article  CAS  Google Scholar 

  6. Ding, H. et al. Cell Rep. 27, 3331–3344.e3336 (2019).

  7. Fennell, D. A. et al. Lancet Oncol. 23, 374–381 (2022).

    Article  CAS  Google Scholar 

  8. Kryukov, G. V. et al. Science 351, 1214–1218 (2016).

    Article  CAS  Google Scholar 

  9. Wu, J. et al. Nature 572, 402–406 (2019).

    Article  CAS  Google Scholar 

  10. Fennell, D. A. et al. Lancet Respir. Med. 9, 593–600 (2021).

    Article  CAS  Google Scholar 

  11. Fennell, D. A. et al. Lancet Oncol. 22, 1530–1540 (2021).

    Article  CAS  Google Scholar 

  12. Forde, P. M. et al. Nat. Med. 27, 1910–1920 (2021).

    Article  CAS  Google Scholar 

  13. Adusumilli, P. S. et al. Cancer Discov. 11, 2748–2763 (2021).

    Article  CAS  Google Scholar 

  14. Pinto, C. et al. Lancet Oncol. 22, 1438–1447 (2021).

    Article  CAS  Google Scholar 

  15. Fennell, D. A. et al. J. Clin. Oncol. 39, 8507 (2021).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mesothelioma Research Programme, Centre for Cancer Research, Department of Genomics and Genome Biology, University of Leicester, Leicester, UK

    Dean A. Fennell & Aleksandra Bzura

Authors
  1. Dean A. Fennell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aleksandra Bzura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dean A. Fennell.

Ethics declarations

Competing interests

D.A.F. has received research grants from Astex Therapeutics, Bayer, Bristol Myers Squibb, Boehringer Ingelheim and Pierre Fabre; fees from Aldeyra, Atara Biotherapeutics, Bristol Myers Squibb, Cambridge Clinical Laboratories, Inventiva and Targovax; and non-financial support from Clovis, Eli Lilly, Roche, Bergen Bio, Bristol Myers Squibb, MSD and Pierre Fabre.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fennell, D.A., Bzura, A. Accelerating innovations in systemic therapy for pleural mesothelioma. Nat Cancer 3, 902–904 (2022). https://doi.org/10.1038/s43018-022-00419-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00419-5

  • Springer Nature America, Inc.

Search

Navigation